Sarepta Therapeutics (SRPT) Projected to Post Quarterly Earnings on Tuesday

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) is expected to announce its Q1 2025 earnings results after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of $2.20 per share and revenue of $685.75 million for the quarter.

Sarepta Therapeutics Stock Up 0.1 %

Shares of SRPT traded up $0.07 during mid-day trading on Tuesday, hitting $61.58. 203,229 shares of the company traded hands, compared to its average volume of 1,419,211. Sarepta Therapeutics has a 1-year low of $48.01 and a 1-year high of $173.25. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $5.97 billion, a PE ratio of 49.39 and a beta of 0.93. The business has a 50 day moving average of $76.41 and a 200 day moving average of $105.15.

Insider Buying and Selling at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now directly owns 27,812 shares of the company's stock, valued at $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.70% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Piper Sandler decreased their target price on shares of Sarepta Therapeutics from $182.00 to $110.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Needham & Company LLC reduced their price target on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a "buy" rating for the company in a research report on Thursday, April 3rd. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a "hold" rating for the company in a research report on Wednesday, March 19th. Morgan Stanley reduced their price target on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an "overweight" rating for the company in a research report on Friday, April 11th. Finally, Scotiabank reduced their price target on shares of Sarepta Therapeutics from $105.00 to $80.00 and set a "sector perform" rating for the company in a research report on Thursday, March 20th. Six analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $158.70.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.